WO2004033431A3 - Hydroxypyrazoles for use against metabolic-related disorders - Google Patents

Hydroxypyrazoles for use against metabolic-related disorders Download PDF

Info

Publication number
WO2004033431A3
WO2004033431A3 PCT/US2003/031509 US0331509W WO2004033431A3 WO 2004033431 A3 WO2004033431 A3 WO 2004033431A3 US 0331509 W US0331509 W US 0331509W WO 2004033431 A3 WO2004033431 A3 WO 2004033431A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
compounds
metabolic
disorders
compositions
Prior art date
Application number
PCT/US2003/031509
Other languages
French (fr)
Other versions
WO2004033431A2 (en
Inventor
Graeme Semple
Young Jun Shin
Original Assignee
Arena Pharm Inc
Graeme Semple
Young Jun Shin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41619302P priority Critical
Priority to US60/416,193 priority
Priority to US41712002P priority
Priority to US60/417,120 priority
Application filed by Arena Pharm Inc, Graeme Semple, Young Jun Shin filed Critical Arena Pharm Inc
Publication of WO2004033431A2 publication Critical patent/WO2004033431A2/en
Publication of WO2004033431A3 publication Critical patent/WO2004033431A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to certain hydroxypyrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the nicotinic acid receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
PCT/US2003/031509 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders WO2004033431A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US41619302P true 2002-10-04 2002-10-04
US60/416,193 2002-10-04
US41712002P true 2002-10-07 2002-10-07
US60/417,120 2002-10-07

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003282679A AU2003282679A1 (en) 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders

Publications (2)

Publication Number Publication Date
WO2004033431A2 WO2004033431A2 (en) 2004-04-22
WO2004033431A3 true WO2004033431A3 (en) 2004-07-29

Family

ID=32096141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031509 WO2004033431A2 (en) 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders

Country Status (2)

Country Link
AU (1) AU2003282679A1 (en)
WO (1) WO2004033431A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AU2004260636A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
PE20050483A1 (en) 2003-10-31 2005-08-25 Arena Pharm Inc TETRAZOLE DERIVATIVES OF FORMULA (I), ITS PHARMACEUTICAL COMPOSITIONS AND PROCESSES TO PRODUCE PHARMACEUTICAL COMPOSITIONS
WO2005051937A2 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
AR054998A1 (en) 2004-12-03 2007-08-01 Schering Corp PIPERAZINAS REPLACED AS AN ANCHANGIST OF CB1, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND FOR THE MANUFACTURE OF MEDICINES
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
CA2677096A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG10201607592PA (en) 2008-12-19 2016-11-29 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
NZ605627A (en) 2010-06-23 2015-06-26 Vertex Pharma Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2694498B1 (en) 2011-04-05 2016-03-30 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103987709B (en) 2011-09-30 2016-09-28 沃泰克斯药物股份有限公司 The method that can be used as the compound of ATR inhibitors of kinases for preparation
EP2751099B1 (en) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN108685922A (en) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 With ATR inhibitor for treating cancer of pancreas and non-small cell lung cancer
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN107501274B (en) 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitor
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
LT3077397T (en) 2013-12-06 2020-01-27 Vertex Pharmaceuticals Inc. 2-AMINO-6-FLUORO-N-[5-FLUORO-PYRIDIN-3-YL]PYRAZOLO[1,5-a]PYRIMIDIN-3-CARBOXAMIDE COMPOUND USEFUL AS ATR KINASE INHIBITOR, ITS PREPARATION, DIFFERENT SOLID FORMS AND RADIOLABELLED DERIVATIVES THEREOF
AU2015271030B2 (en) 2014-06-05 2019-05-16 Vertex Pharmaceuticals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS549279A (en) * 1977-06-24 1979-01-24 Ishihara Sangyo Kaisha Ltd Tetrazolypyridylketone and herbicides coatining the same
US4857542A (en) * 1985-05-20 1989-08-15 Mitsubishi Chemical Industries Limited Prophylactic and therapeutic composition for circulatory disorders and method of treatment
JPH0338586A (en) * 1989-07-04 1991-02-19 Nippon Soda Co Ltd Substituted pyridine derivative, its production and herbicide
US5183825A (en) * 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
WO2001094339A1 (en) * 2000-06-09 2001-12-13 Syngenta Participations Ag Substituted pyridine herbicides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS549279A (en) * 1977-06-24 1979-01-24 Ishihara Sangyo Kaisha Ltd Tetrazolypyridylketone and herbicides coatining the same
US4857542A (en) * 1985-05-20 1989-08-15 Mitsubishi Chemical Industries Limited Prophylactic and therapeutic composition for circulatory disorders and method of treatment
JPH0338586A (en) * 1989-07-04 1991-02-19 Nippon Soda Co Ltd Substituted pyridine derivative, its production and herbicide
US5183825A (en) * 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
WO2001094339A1 (en) * 2000-06-09 2001-12-13 Syngenta Participations Ag Substituted pyridine herbicides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIYAMA, RYUZO ET AL: "Pyrazolyl pyridyl ketones", XP002271467, retrieved from STN Database accession no. 90:186940 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UEDA, AKIYOSHI ET AL: "Preparation of pyrazolylpyridine derivatives as herbicides", XP002271466, retrieved from STN Database accession no. 115:29323 CA *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
WO2004033431A2 (en) 2004-04-22
AU2003282679A8 (en) 2004-05-04
AU2003282679A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004033431A3 (en) Hydroxypyrazoles for use against metabolic-related disorders
WO2006069242A3 (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
TNSN06150A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2006017836A3 (en) 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MA29799B1 (en) ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
WO2003063864A3 (en) Heterocyclic compounds which are active as inhibitors of beta lactamases
WO2006011050A3 (en) Pyridine derivatives
WO2003066594A3 (en) 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
NO330171B1 (en) Chiral oxazole-arylpropionic acid derivatives, processes for the preparation thereof, pharmaceutical compositions containing them, such compounds for use as therapeutically active substances, and such compounds for the treatment and / or prevention of disease
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
GEP20084406B (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
NO20051901L (en) New antimycobacterial compositions and pyrrole derivatives such as antimycobacterial compositions
MA31142B1 (en) HETEROARYL DERIVATIVES OF PYRROLIDINYL AND PIPERDINYL KERONES.
MY148529A (en) Formulations of quinolinones
WO2005051937A3 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
MY142739A (en) Carbostyril derivatives for accelerating salivation
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
WO2007063384A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP5765738B2 (en) Rosuvastatin and atorvastatin derivatives
WO2006110173A3 (en) Novel compounds
WO2005118558A3 (en) Pyrimidine compounds and use thereof

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP